Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 12/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 4/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22035026 | 0.87 | CA1 (0.46) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL22079924 | 0.80 | CYP2D6 (0.48) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL19001229 | 0.80 | CA1 (0.53) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL25974779 | 0.80 | CA1 (0.53) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL24780831 | 0.79 | CA1 (0.44) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL22034842 | 0.78 | GRIK1 (0.33) | — | |
| SCHEMBL17951340 | 0.78 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL7515863 | 0.78 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL19166265 | 0.78 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL22034841 | 0.78 | GRIK1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12246008-B2 | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME LLC (US) | 2025-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12246008-B2 | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels | TRPV1, SCN7A, SCN1A | CA1 2378/4885CA2 496/4885CA7 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.